CA-SETI-INSTITUTE
The SETI Institute, a non-profit scientific research organization, announced today a philanthropic gift of $200m from the estate of Franklin Antonio, a visionary supporter and catalyst of the work of the SETI Institute for more than 12 years. Co-founder of communications chip company, Qualcomm, Antonio passed away on May 13, 2022, leaving behind an extraordinary legacy to enable breakthrough science in the search for intelligent life beyond our world.
With more than 100 scientists actively conducting research across 173 separate programs, the SETI Institute explores six key science disciplines: Astronomy and Astrophysics; Exoplanets; Planetary Exploration; Astrobiology; Climate and Bio-geoscience; and the Search for Extraterrestrial Intelligence (SETI).
“Guided by our core mission and Franklin Antonio’s vision, we now have the opportunity to elevate and expedite our research and make new discoveries to benefit all humanity for generations to come,” said SETI Institute President & CEO Bill Diamond. “In his memory, the SETI Institute will continue its pursuit of one of the biggest and most profound questions in all of science, a question as old as humanity itself – are we alone in the universe?”
This gift enables the SETI Institute to undertake more missions and expand research priorities to push the boundaries of human knowledge in exploring life beyond our planet and the origins of life here on Earth. Examples include:
- Establish postdoctoral fellowships and internal grants for science and education programs
- Enable the SETI Institute’s research base to expand and extend its reach globally through new international collaborations
- Develop new educational programs and initiatives, particularly focused on reaching and engaging underserved communities
- Support the development of innovative observational technologies and analytical instruments
“Not only was Franklin the primary benefactor of SETI research at the Allen Telescope Array (ATA), but he was an integral part of the technical team. His extraordinary knowledge of communications technology was invaluable in upgrading the ATA to the world-class radio telescope instrument it is today,” said Dr. Andrew Siemion, Bernard M. Oliver Chair of SETI Research at the SETI Institute and Director of SETI Research at the University of Oxford.
Currently, SETI-focused projects are eligible for only limited federal funding through research grants and otherwise depend entirely on philanthropic support and private funding. As such, Antonio’s gift will also serve to permanently endow core SETI programs and foster new global partnerships.
“This gift will impact all research domains of the SETI Institute,” said Dr. Nathalie Cabrol, Director of the Carl Sagan Center for Research. “It will provide our teams the freedom to pursue their own science priorities, and to examine the technological, philosophical and societal impact of their research on our daily lives here on Earth.”
About The SETI Institute
Founded in 1984, the SETI Institute is a non-profit, multi-disciplinary research and education organization whose mission is to lead humanity's quest to understand the origins and prevalence of life and intelligence in the universe and share that knowledge with the world. Our research encompasses the physical and biological sciences and leverages data analytics, machine learning, and advanced signal detection technologies. The SETI Institute is a distinguished research partner for industry, academia, and government agencies, including NASA the Department of Energy and the National Science Foundation. https://www.seti.org/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231108082387/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased16.7.2025 09:15:00 CEST | Press release
Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein. This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily i
The Future of Connectivity Starts Here: Network X Returns to Paris October 14 - 1616.7.2025 09:00:00 CEST | Press release
Show Reconvenes at Paris Expo Porte de Versailles with Global Representation of Industry Leaders and Telco Experts Network X 2025 - the only event that brings the fixed and mobile markets together - returns to Paris Expo Porte de Versailles October 14 - 16. Built for telecom's top players, this annual show drives business model innovation and monetisation of next-generation fixed, mobile, satellite and transport networks through AI and cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716595903/en/ Speaker on Headliners Stage at Network X 2024 New to Network X in 2025 are specialty events designed to deliver expert insights on trending topics including Data Center World and two Expo Stages for Fixed-Line and Mobile. More than 5,500 telco network infrastructure professionals will gather alongside 1,500 telcos to learn from six program tracks highlighting the latest advancements in Fibre, Wi-Fi Networks and Services, IP
Skechers AERO Series Opens New Chapter of Technical Running Innovation16.7.2025 09:00:00 CEST | Press release
New Collection Features an Evolution in Design that Cuts Through the Wind for That Aerodynamic Feel on Every Run Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716754749/en/ Introducing the Skechers AERO Series of technical running shoes: Skechers AERO Burst, Skechers AERO Spark, and Skechers AERO Tempo (L-R). “Recently launched in North America and Asia, the AERO Series leverages innovative technologies to elevate our signature comfort that’s now available to runners in Europe,” said Ben Stewart, Vic
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom